Handelsavisen
prelaunch
Companies Healthcare 6821.HK
68
6821.HK HKEX Pharmaceuticals

Asymchem Laboratories (Tianjin) Co Ltd

HK$96,40
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,7B HKD
P/E
EV / Rev
Div yield
1,14 %
Op margin
18,9 %
ROE
6,4 %
Net margin
17,0 %
Debt / equity
0,02
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company that provides contract research and development services to the pharmaceutical and biotechnology industries, primarily generating revenue through service contracts and product sales.

Business. Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company headquartered in Tianjin that operates within the Healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 6821.HK. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY7 analysts
6 buy1 hold0 sell
Avg 12m price target126,87

Analyst recommendations

7 analysts · consensus Buy
Buy6
Hold1
Sell0
12-month price target
126,87
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
7 analysts · indicative
Ownership
not yet wired
Profitability
6,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6821.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6821.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company headquartered in Tianjin that operates within the Healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 6821.HK. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Asymchem Laboratories maintains a strong liquidity position, with a current ratio of 5.85 and cash and equivalents amounting to CNY 3.4 billion, which is significantly higher than the industry median. The company's price-to-book ratio is 0.15, indicating that the market values the company at a discount to its book value. The low debt-to-equity ratio of 0.02 suggests a conservative capital structure with minimal leverage.

    Profitability metrics show that Asymchem's return on equity (ROE) is 6.42%, and return on assets (ROA) is 5.59%, both of which are below the industry median for pharmaceutical companies. The company's net income of CNY 1.13 billion represents a healthy margin, but the low ROE and ROA suggest that the company is not generating returns at a level that significantly outperforms its peers.

    Geographically, Asymchem's revenue is primarily concentrated in China, with a significant portion of its operations based in Tianjin. The company does not disclose detailed segment data, but its business is largely focused on pharmaceutical research and development services. This concentration may expose the company to regulatory and economic risks specific to the Chinese market.

    Looking ahead, Asymchem is expected to maintain a stable growth trajectory, with analysts forecasting a mean price target of CNY 126.87, which is 33.8% higher than the current market price of CNY 94.85. The company's revenue has shown consistent growth, and its operating cash flow of CNY 1.41 billion supports its ability to fund operations and invest in future growth.

    The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is supported by the fact that the number of shares outstanding has remained stable, with no significant changes in the past year. The company's conservative capital structure and strong cash reserves further mitigate liquidity concerns.

    Recent events, including analyst estimates and price targets, indicate a positive outlook for Asymchem. The mean recommendation from analysts is 1.86, which is a strong buy rating, with 2 strong buy, 4 buy, and 1 hold ratings. The high price target of CNY 136.60 suggests that some analysts are optimistic about the company's future performance.

    Key takeaways
    • Asymchem Laboratories has a strong liquidity position with a current ratio of 5.85 and CNY 3.4 billion in cash and equivalents.
    • The company's profitability metrics, including ROE and ROA, are below the industry median, indicating room for improvement in generating returns.
    • Revenue is primarily concentrated in China, which may expose the company to regulatory and economic risks specific to the region.
    • Analysts have a positive outlook, with a mean price target of CNY 126.87, which is 33.8% higher than the current market price.
    • The company's risk profile is characterized by low liquidity and dilution risks, supported by a stable share count and conservative capital structure.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$96,40
    Market cap
    HK$2.64B
    Enterprise value
    -HK$454.0M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    -0.3x
    P / B
    0.1x
    P / Tangible book
    0.1x
    Tangible book
    HK$17.64B
    Net cash
    HK$3.09B
    Current ratio
    5.8
    Debt / equity
    0.0
    ROA
    5.6%
    ROE
    6.4%
    Cash conversion
    124.0%
    CapEx / revenue
    -19.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    3,95
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    7
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate3,95
    Revenueno estimateno estimate8,0B CNY
    Operating incomeno estimateno estimate1,5B CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution7 analysts
    Strong buy2
    Buy4
    Hold1
    Sell0
    Strong sell0
    12-month price targetHK$126,87 · Median HK$128,20
    Low HK$115,43High HK$136,60
    Operating income · consensus1,5B CNY
    EPS surprise
    −20,1 %
    reported vs consensus · miss
    Revenue surprise
    −17,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$115,43
    MeanHK$126,87
    MedianHK$128,20
    HighHK$136,60
    SpotHK$96,40
    +31.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin18,9 %Above P75
    Net Margin17,0 %Above P75
    ROE6,4 %Above median
    Capex / Rev-19,1 %Bottom quartile
    D/E0,02Above median
    Cash Conv1,24Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Asymchem Laboratories (Tianjin) Co Ltd Market data — financials · 2026-05-27
    • Asymchem Laboratories (Tianjin) Co Ltd Market data — analyst estimates · 2026-05-27
    • Asymchem Laboratories (Tianjin) Co Ltd Market data — ESG · 2026-05-27

    Ownership & reference

    Leadership

    • Chaoyong ChenExecutive Vice President
    • Yi XiaoSenior Vice President
    • Yingwei JiangExecutive Vice President

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6821.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage